FDA ACTIONS
FDA has issued 3 draft guidances for the development of biosimilar versions of approved biologic products, which will help flesh out the abbreviated approval pathway created by the Patient Protection and Affordable Care Act signed into law in 2010. » More |
MEDICATION SAFETY
Researchers are warning pediatricians, pediatric hospitalists, and intensivists of the potential for intravenous acetaminophen dosing errors, especially in young patients under 2 years old. » More |
|
There was an increased risk of acute infection among long-term care residents who visited hospital emergency departments, according to a study published online January 23 in the Canadian Medical Association Journal. » More |
|
Nursing home residents with dementia who use average doses of selective serotonin reuptake inhibitors (SSRIs) are 3 times more likely to have a fall resulting in injury compared with those who don’t use SSRIs, according a study published online January 18 in the British Journal of Clinical Pharmacology. » More |
Editor's Pick
American Heart Association: Rivaroxaban lowers risks in patients with acute coronary syndrome
The oral anticoagulant rivaroxaban lowered the risk of death, heart attack, and stroke in acute coronary syndrome patients, according to a study presented at the American Heart Association's Scientific Sessions 2011 in Orlando, Fla., in mid-November. » Click here. |
CONTINUING EDUCATION
Also known as syndrome X or metabolic syndrome, this condition can lead to diabetes, hypertension, and cardiovascular disease. For patients, pharmacists are an ideal source of information and support. Earn up to 2 CPE credits. » Click here to login and take the exams. |
FDA ACTIONS
An FDA advisory panel recommended against using denosumab (Xgeva, Amgen) to delay or prevent the spread of castration-resistant prostate cancer at high risk for bone metastases. » More |
|
FDA has granted priority review to crofelemer 125-mg tablets (Salix Pharmaceuticals) for the control and symptomatic relief of diarrhea in patients with HIV/AIDS on anti-retroviral therapy. » More |
|
FDA approved axitinib (Inlyta, Pfizer) to treat patients with an advanced kidney cancer called renal cell carcinoma who have not responded to another drug for this type of cancer. » More |
|
FDA has approved exenatide extended-release for injectable suspension (Bydureon, Amylin and Alkermes) — the first once-weekly treatment for type 2 diabetes. » More |
|
FDA has approved Janumet XR tablets (Merck), a new treatment for type 2 diabetes that combines sitagliptin, which is the active component of Januvia, with extended-release metformin. » More |
|
FDA has approved linagliptin/metformin hydrochloride (Jentadueto, Boehringer Ingelheim and Eli Lilly) tablets, a new tablet that provides a single-tablet treatment option, taken twice-daily, for adult patients who need to control their blood sugar. » More |
|
FDA declined approval of the diabetes drug dapagliflozin (Bristol-Myers Squibb and AstraZeneca), based on the recommendations of 1 of its advisory committees. » More |
Survey
1) A nurse or nurse case manager performs MTM in my health system
2) A physician performs MTM or medication reconciliation in my health system
3) A pharmacist performs MTM or medication reconciliation in my health system
4) More than 1 different type of healthcare provider performs MTM and/or medication reconciliation in my health system
Respond here and see what your colleagues think too.
Want to see the results of our last survey regarding the use of aliskiren-containing medications? Click here. |
|
Digital Edition |
|
|
|
You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.
Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or
fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
|
|
|
